English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose  To investigate the intraocular pressure (IOP)-lowering efficacy and tolerance of brinzolamide/brimonidine fixed combination (BBFC) under real-life conditions in a tertiary glaucoma centre.    Methods  Medical records of all ocular hypertensive and open-angle glaucoma patients ( n  = 52) treated with BBFC were retrospectively analysed.    Results  Thirty-nine patients had primary open-angle, 6 exfoliative, 2 pigment, 1 normal tension and 1 juvenile open-angle glaucoma and 3 ocular hypertension. The prior therapy was a prostaglandin analogue (PG) ( n  = 4), PG/timolol ( n  = 20), PG/timolol and topical carbonic anhydrase inhibitor (CAI;  n  = 19), timolol/CAI ( n  = 1), PG and CAI ( n  = 4), timolol/pilocarpine and PG ( n  = 1), timolol/brimonidine and PG ( n  = 1) and timolol/brimonidine, PG and CAI ( n  = 2). These were simplified to PG/timolol and BBFC ( n  = 41), PG and BBFC ( n  = 9), timolol and BBFC ( n  = 1) and timolol/pilocarpine, PG and BBFC ( n  = 1). The IOP on the study eyes was 21.2 ± 3.7 mmHg before and 16.9 ± 2.6, 16.0 ± 2.2, 17.6 ± 3.1 and 18.0 ± 3.1 mmHg after the introduction of BBFC at month 1, 3, 6 and 12, respectively ( p  &lt; 0.0003 for all time points compared to baseline,  p  = 1.0 for all other comparisons). Thirty-one patients (59.6%) experienced no adverse event, 17 (32.7%) reported ocular and 6 (11.5%) systemic adverse events. BBFC therapy was terminated on 27 patients (51.9%): on 19 (36.5%) due to adverse events and on 8 (15.4%) due to insufficient IOP reduction.    Conclusion  In real-life practice, the introduction of BBCF allows significant and clinically meaningful IOP reduction and therapy simplification in glaucoma patients requiring complex medication, but in more than one third of the patients it is not tolerated due to adverse events.

Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre